KLHDC7A

Across TCGA pan-cancer cohorts, KLHDC7A Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated KLHDC7A data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher KLHDC7A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KLHDC7A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, READ, and LUAD are the cancer types where KLHDC7A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.223	0.543	.009	24	view →
READ	DFS	Median	III,IV	0.082	0.746	<.001	9	view →
LUAD	OS	Median	II,III,IV	0.245	0.749	.019	6	view →
UCEC	DFS	Median	All	0.961	0.627	.025	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
CESC	DFS	Median	All	0.563	0.825	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

KLHDC7A–OV (DFS)

Open the OV breakdown →